Skip to content

Press Releases

Swedish

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

Asarina Pharma AB (publ) Annual Report 2020 released

Asarina Pharma CEO Peter Nordkild: “2020 and early 2021 have seen new research and additional data confirming and consolidating the efficacy and potential of our flagship compound Sepranolone. As we continue forward into an eventful 2021, we remain confident of the significant clinical relevance of Allopregnanolone, and the ability of our flagship compound Sepranolone to…

Full PDF

Asarina Pharma AB (publ) Q4 / Year End 2020 report released

Asarina Pharma CEO Peter Nordkild: “2020 was a turbulent, challenging year for all of us – yet at Asarina Pharma we begin 2021 with continued confidence in the high potential of our flagship compound Sepranolone. We are on schedule to publish our topline results for our Phase IIa Menstrual Migraine study in June 2021, and…

Full PDF

New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome

(Stockholm, 11 February 2021.) Two sets of new preclinical data presented by Prof Marco Bortolato (Univ. of Utah) confirm that Sepranolone suppresses tics in Tourette Syndrome (TS) and restores Prepulse Inhibition (PPI), a key phenomenon related to TS with no observable side-effects. The new data also point towards the overproduction of Allopregnanolone in acute stress…

Full PDF

Asarina Pharma AB (publ) Q3 2020 report released

Asarina Pharma CEO Peter Nordkild: “During the third quarter 2020 we have been firmly focused on execution. We achieved full enrolment for our Phase IIa Menstrual Migraine study—despite tough Covid-19 restrictions, and continued preparations for our Phase IIa study in Tourette syndrome. We remain confident of completing both studies on schedule, so realizing our vision…

Full PDF

Full patient enrolment in Phase IIa Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) has reached full patient enrolment in its Phase IIa menstrual migraine (MM) study. 158 women have been recruited as scheduled at seven test centers across Sweden and Finland despite Covid-19 restrictions. Sepranolone, the endogenous compound being tested for MM, is the first therapy to focus exclusively on menstrual…

Full PDF
Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders 2023-05-23 09:02 Regulatory
Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in...
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ) 2023-05-22 11:15 Regulatory
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on...
Asarina Pharma’s positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America 2023-05-05 13:33
The Phase IIa results demonstrated that Sepranolone could become the first-line pharma treatment for Tourette as it showed competitive tic reduction and...
Asarina Pharma AB (publ) releases Annual Report 2022 2023-04-28 20:30 Regulatory Annual
The full Annual Report 2022 is available on: https://asarinapharma.com/investors/financial-reports/ Research and Development: This year, Asarina’s...
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL) 2023-04-18 10:39 Regulatory
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate...
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome 2023-04-01 14:20 Regulatory
THE STUDY: This was an open label, dual center, add-on study, randomizing 28 Tourette Syndrome patients, 20 males/8 females, 3 adolescents/25 adults between...
Asarina Pharma AB (publ) releases Year-End Report 2022 2023-02-27 08:30 Regulatory Interim
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Recruitment completed: patient recruitment to Phase IIa study in Tourette completed in October 2022. A total of...
Last Patient Last Visit for landmark Tourette Syndrome study 2023-02-02 09:45 Regulatory
A total of 28 patients took part in the study: a ‘control group’ of 9 patients who received their standard treatment, plus an ‘active...
Patient recruitment completed in landmark Tourette syndrome study 2022-10-14 09:50 Regulatory
Enrollment of adult patients started at the Bispebjerg University Hospital in Copenhagen in February 2022, while teenage patients have been enrolled at...
Extensive new preclinical study significantly increases the Translatability of Asarina Pharma’s findings on key stress mechanism implicated in Tourette Syndrome and OCD 2022-10-06 08:30 Regulatory
A new study, the fourth and most comprehensive in a series of four (1), reconfirms that acute stress increases the overproduction of the powerful neurosteroid...
Next